Physician profile
Suzanne White
NPI 1194904789
$2,768.22
in general payments reported to CMS, 2019-2025
19 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $621 · 2023: $635 · 2024: $649 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $564.12 | 2022-2024 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $345.18 | 2021-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $239.83 | 2024-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $234.48 | 2022-2023 | Jornay Pm |
| Corium, LLC | $193.91 | 2021-2023 | Azstarys |
| Abbvie INC. | $150.16 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $124.69 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $122.80 | 2024 | Auvelity |
| Acadia Pharmaceuticals INC | $117.93 | 2025 | Nuplazid |
| Tris Pharma INC | $115.15 | 2024 | Quillivant, Dyanavel Xr, Quillichew Er |
| Supernus Pharmaceuticals, INC. | $110.09 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $101.15 | 2022-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $96.09 | 2022 | |
| Neurocrine Biosciences, INC. | $93.54 | 2022 | |
| Vanda Pharmaceuticals INC. | $82.91 | 2025 | Fanapt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.02 | 2025 | Vyloy |
| Organon LLC | $18.13 | 2023 | Nexplanon |
| Coopersurgical, INC. | $17.14 | 2022 | |
| Indivior INC. | $15.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.